Abstract. Detection of leukemia at the early stage with high sensitivity is a significant clinical challenge for clinicians. In the present study, we developed a sensitive detector consisting of the product of oligonucleotides hybridized with semiconductor quantum dots (QDs) to generate a stronger fluorescent signal so that leukemic cells can be captured. In the present study, a biotin-modified Sgc8 aptamer was used to identify CCRF-CEM cells, and then biotin-appended QDs were labeled with the aptamer via streptavidin and biotin amplification interactions. We described the complex as QDs-bsb-apt. CEM and Ramos cells were used to assess the specificity and sensitivity of the novel complex. These results revealed that the complex could be more effective in diagnosing leukemia at the early stage. In conclusion, an innovative structure based on aptamer and QDs for leukemia diagnosis was provided. It has the potential to image tumor cells in vitro or in vivo and to realize the early diagnosis of disease. Furthermore, it may be used to provide guidance for clinicians to implement individualized patient therapy.
Introduction
It is well known that leukemia, bone marrow or blood cancer, is one of the most common and aggressive cancers (1) , particularly in children and adults (2) . For conducting effective treatment of this disease, accurate and sensitive diagnoses are essential. In previous studies, DNA-silver nanocluster (3, 4) , mass spectrometry (5) and aptamer-DNA concatamer-quantum dot probes (6) were used as a complex to detect leukemia cells. However, such complexes have serious drawbacks, such as insensitivity and high expense, and sophisticated instruments and meters are required. Hence, a simpler strategy with higher sensitivity is demanded to accurately detect leukemia cells.
Aptamers, special three-dimensional structures, can be obtained via SELEX (systematic evolution of ligands by exponential enrichment) in vitro process (7, 8) . The simulated single-stranded oligonucleotides can selectively recognize as well as combine with a wide range of objects, such as drugs, proteins and even entire cells (9, 10) . In comparison with conventional antibodies, aptamers show some superiority, including the capability of being synthesized easily with low expense, the ability to be purified to a high level, lack of immunogenicity and good stability (11) (12) (13) , which are helpful to detect cancer cells (14, 15) . The Sgc8 aptamer, selected based on the whole cell (16) , has been proven to have characteristics including high binding-affinity and specificity for human T-acute lymphocytic leukemia (T-ALL) cell lines (17) . CCRF-CEM, a T-ALL cell line, was reported to be used as a target cell, and Romas, a human Burkitt's lymphoma cell line was reported to be used as a negative control.
Fluorescent quantum dots (QDs) and nanometer semiconductors, have been used as photographic developers in the construction of diagnostic instruments and antitumor nanodrugs (18) (19) (20) (21) . They have attracted widespread attention due to their superior fluorescent features. Unlike precious metal nanoparticles and traditional organic dyes, QDs exhibit excellent biocompatibility, low toxicity, resistance to light bleaching, and allows stable and easy modulation (22) . Several studies have confirmed that QDs are appropriate and efficient for PDT and bio-imaging (23) (24) (25) . Furthermore, they can be applied to detect and sense biomarkers, molecular markers, and cell surface receptors when being linked with some guiding instruments or targeting molecules (26) (27) (28) .
In the present study, we developed an innovative complex based on the Sgc8 aptamer and QDs for the diagnosis of Preparation of the QD-aptamer complex. Biotin-QD525 was decorated by streptavidin, and then conjugated with the biotin-modified Sgc8 aptamer. Firstly, streptavidin and biotinQDs were mingled at a ratio of 10:1 and incubated for 40 min at 37˚C to obtain streptavidin-QDs. Secondly, QDs-bsb-apt was synthesized followed by addition of the biotin-modified Sgc8 aptamers and incubated sequentially at a ratio of 40:1. Then, the mixture was co-cultured for 40 min at 37˚C. Finally, unconjugated biotin-aptamers were eliminated, and conjugated QDs-bsb-aptamer complexes were retrieved by centrifugal filtration at 14,000 rpm for 25 min. Following washing in PBS (10 mM; pH, 7.4), an ultrasonic processor (Scientz-IID; Ningbo Scientz Biotechnology Co., Ltd., China) was used to disperse the aggregated conjugates by sonication (25 kHz; amplitude, 15 µm; sonication time, 3 min) and stored at 4˚C. Cell imaging. CEM and Ramos cells were cultured in a 6-well cell culture plate at a density of 3-4x10 5 cells/ml. After incubation for 24 h, the cells were then placed on ice for 30 min to avoid non-specific binding. The cells were washed with cold PBS three times, and then fixed with 4% polyoxymethylene (Sigma-Aldrich). After incubation with the complexes (10 nM) in binding buffer (1 mM CaCl 2 , 1 mM MgCl 2 , 1 mg/ml bovine serum albumin and 10% FBS) on ice for 50 min, the cells were then washed three times. Next, the cells were mounted onto microscope slides using 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) (Life Co., USA) to perform imaging analysis via a fluorescence microscope (DS-Ri1; Nikon Corporation, Tokyo, Japan).
MTT assay. Evaluation of cell toxicity of the QDs-bsb-apt was carried out by the methylthiazol tetrazolium (MTT) assay. The process involved in the MTT assay is briefly described as follows. Firstly, 293T cells (2x10 4 in 100 µl) were seeded into 96-well plates and cultured overnight in an incubator. Then, the cells were treated with the complexes (10, 20, 30, 50 and 100 nM) or PBS as a control group for 24 or 48 h. After that, 10 µl of MTT (5 mg/ml) was added to each well and the cells were incubated for a further 3 h at room temperature in a lucifugal place. Before adding the ethanol/dimethyl sulfoxide (DMSo) into the well, the medium in the well was discarded. After 2 min, the absorbance was tested at λ=570 nm with an ELISA microplate reader (Thermo Scientific, USA).
Histological analysis. Evaluation of systemic toxicity was carried out by analysis of the histologic evidence from the heart, liver, kidney, spleen and lung. Six-week-old nude mice were administered an intravenous injection of QDs-bsb-apt (15 mg/kg) or PBS in the control experiments through the tail vein. Then, changes in the clinical behavior of the treated mice were monitored every day. Mice were sacrificed after being treated for 20 days, for histological examination. Tissue samples of the organs, which were preserved in 10% formaldehyde solution, were dehydrated, following a routine strategy, and then embedded in paraffin. The paraffin sections were deparaffinized and immersed in distilled water, following a routine strategy. Then, hematoxylin and eosin staining was carried out in the following steps: i) coloration with hematoxylin solution for 5-15 min; ii) separation of color with acid or ammonia solution for a few seconds, respectively; iii) washing with running water for half an hour; iv) dehydration in 70% and 90% alcohol for 10 min sequentially; v) eosin staining for 2-3 min; and vi) dehydration, clearing and mounting with neutral gums. The negative control group was implemented using the same steps as described above. Hematoxylin and eosin solutions were purchased from Beijing Solarbio Co., China.
Statistical analyses. Student's t-test was applied to make comparisons and one-way analysis of variance (ANoVA) was applied to compare three means or more. Data are shown as means ± SD. All statistical analyses were two-tailed. P≤0.05 was considered to indicate a statistically significant result. Statistical analyses were performed using GraphPad Prism software (graphPad Software, San Diego, CA, USA).
Results

Experimental principle.
Recently, QDs and aptamers have been combined and are widely used for cell imaging and biomedical application. In most cases, QD-aptamer conjugates are connected directly for cell recognition, such as biotin-QDs conjugated with a streptavidin-aptamer (29) . Using such an approach, the aptamers in recognizing target cells may be baffled by steric hindrance caused by QDs, and the limited amplification may cause insensitive examination in detection processing. To avoid these issues, a strategy of linking biotinQDs and the biotin-aptamer was proposed in which biotin-QDs were coupled to streptavidin, and the streptavidin-appended QDs were then bound to the biotin-aptamer to allow the target cancer cells to be detected by fluorescence microscopy and flow cytometry (Fig. 1) . CEM cells, a common leukemia cancer cell line, were treated as target cells. Sgc8, an aptamer of CEM cells, that has high affinity and specificity, was selected by cell-SELEx. This method may provide an efficient approach for tumor cell detection.
Characterization of the QDs-bsb-apt complex.
Various characteristics of the prepared QDs-bsb-apt complex were analyzed via the following methods. Transmission electron microscopy (TEM; H-7650; Hitachi, Ltd., Tokyo, Japan) was employed to image the dissemination and the size. It was observed, via the image, that the QDs-bsb-apt complexes were well disseminated and the size was increased (Fig. 2A) . The hydrodynamic diameter of the QDs-bsb-apt complexes was tested by dynamic light scattering. It was 18.92±3.05 nm (Fig. 2C) . The fluorescence emission peak of the QDs with or without the aptamer was 525 nm and the absorbance peak of the aptamers with or without QDs was 260 nm (Fig. 2D) . Electrophoretic mobility shift assay was performed using 3% agarose gel electrophoresis. As shown in Fig. 2B , the band in lane 2 indicates the QDs-bsb-apt complex. Its size is >500 bp. The band in lane 1 represents the aptamer alone. Its size is ~50 bp).
Fluorescence microscopic analysis demonstrates the high sensitivity of the detection of leukemia cells using
QDs-bsb-apt in buffer. At first, feasibility analysis of the QDs-bsb-apt strategy was carried out using fluorescence microscopy. Human Burkitt's lymphoma Romas cells were used as negative control and the random DNA library (lib) was used as a control sequence. In the fluorescence images, CEM cells exerted a distinctly stronger fluorescence intensity on their surface with the presence of QDs-bsb-Sgc8 than that of FITC-Sgc8, while no fluorescence signal was observed for the random library (Fig. 3A) . When CCRF-CEM cells were replaced by Ramos cells, no obvious fluorescence signal was observed (Fig. 3B ). This result indicated that due to the the specific properties of the Sgc8 aptamer, QDs-bsb-Sgc8 complexes were able to be applied in the detection of the CEM cells with high sensitivity.
Flow cytometric analysis demonstrates the high sensitivity of detection of leukemia cells using QDs-bsb-apt in serum.
Flow cytometric analysis confirmed that the positive CEM cells shown a stronger fluorescent signal property in serum than the QDs-bsb-Lib, Ramos cells and the FITC-Sgc8 (Fig. 4) . CEM cells (71.6%) could be detected by employing the QDs-bsb-Sgc8 complex, while 57.5% of cells were detected by FITC-Sgc8. The detection efficiency of QDs-bsb-Sgc8 was 1.2-fold higher than the traditional organic dye modified aptamer FITC (Fig. 4) .
The QDs-bsb-apt complex exhibits non-toxicity. MTT assay demonstrated that various concentrations of the QDs-bsb-apt complexes were non-toxic to normal cells such as 293T when co-incubated with the QDs-bsb-apt complexes (Fig. 5A) .
Additionally, after injecting the QDs-bsb-apt complexes into nude mice, hematoxylin and eosin staining was conducted. The staining results demonstrated that the complexes were non-toxic to the entire organism (Fig. 5B) .
Discussion
The synthesis of an aptamer with quantum dots (QDs) in this strategy is a simple and efficient method for generating a complex to detect tumor cells. Such a complex possesses the characteristics of high and specific affinity, low immunogenicity, high photoluminescence quantum yield and a remarkable high extinction ratio. The synthesis of the Sgc8 aptamer with QDs creates a hybrid complex possessing properties from both the aptamer and the QDs. The Sgc8 aptamer provides specific binding to CEM cells, while the QDs supply a sensitive signal for accurate detection.
To demonstrate that the QDs-bsb-apt complex was synthesized successfully, various properties were assessed. TEM imaging and hydrodynamic diameter detection showed that the complexes were satisfactory. The increased size and its narrow distribution suggested that the complexes were uniform and well-proportioned. Fluorescence emission spectra and absorbance of the nucleic acid showed that biotin-QDs modified by the biotin-aptamer preserved the characteristics of the aptamers and the superior spectral properties of the QDs after modification. To further determine the formation of the QDs-bsb-apt complex, electrophoretic mobility shift assay was performed using agarose gel electrophoresis. QDs-bsb-apt was hardly run on the gel, which indicated that the complex was synthesized successfully and unconjugated aptamers were removed.
To illustrate the sensitive detection of leukemia cells using the QDs-bsb-Sgc8 complex, fluorescence microscopy and flow cytometric analysis were carried out. The fluorescent images demonstrated that the CEM cells incubated with QDs-bsb-Sgc8 exhibited stronger fluorescent intensity than that with FITC-Sgc8, which indicated that the QDs-bsb-apt complex had the ability to target cancer cells specifically. Furthermore, the efficiency of detection of the complex was higher than that of the FITC-apt. In the flow cytometric analysis, we observed some shift in the fluorescence intensity among the positive and control samples, suggesting that the sensitivity of this complex was higher. We presumed that the reason for this was that our method of synthesis of the QDs-bsb-apt complex facilitated the binding of more aptamers with QDs to increase the specificity and fluorescence intensity. on the basis of the above results of the fluorescence imaging and the flow cytometric analysis, we conclude that the sensitivity of the QDs-bsb-apt complex was better than that of the FITC-apt complex.
To confirm the non-toxicity of the QDs-bsb-apt complex, MTT assay and hematoxylin and eosin staining of histological sections were executed. The results showed that the complex was non-toxic to normal cells and to the whole organism, which suggests that the complex could not only be safely used as a detector in vitro, but also has the potential to be used safely in vivo for tumor assessment or treatment. After referring to the reported literature, it was quite meaningful that the present study described the toxicity of the QDs-bsb-apt complex for the first time, which could lay a foundation for further research on the aptamer-conjugated QD complex.
In the previous study, the Sgc8 aptamer selected by Shangguan et al (16) was combined with organic dyes or metal elements. For instance, aptamer-silver conjugates were used as theragnostic agents for specific cancer cell therapy and fluorescence-enhanced cell imaging by Li et al (3) . In addition, aptamer-DNA concatamer-quantum dots probes were used for selective and ultrasensitive detection of cancer cells by Liu et al (6) , and a DNA-silver nanocluster fluorescence was applied in cancer cell detection by Yin et al (4) . These conjugates were applied to capture leukemia cells for detection or cure. The present study extends the previous research: i) by demonstrating that QDs conjugated with the Sgc8 aptamer can detect CEM cells efficiently; ii) by demonstrating that the method of conjugating biotin-QDs with biotin-Sgc8 aptamer through coupling of biotin-QDs to streptavidin is more sensitive than the FITC-labeled aptamer directly; and iii) by proving the non-toxicity of the QDs-bsb-apt complex at the cell and systemic level.
In summary, an innovative structure based on aptamer and QDs for leukemia diagnosis was provided. We showed that QDs-bsb-Sgc8 can recognize CEM cells specifically and sensitively. This complex exhibits properties of both the aptamer and QDs, including specificity of targeting and sensitivity to fluoresce. The connections to chemistry also enable it to be used for tumor cell imaging in vitro or in vivo, for clinical application to realize the diagnosis of disease at the early stage of the development of tumors. Furthermore, future investigations may focus on constructing a drug transporter combined with such a complex, which could be used for simultaneously treating and detecting tumors without toxicity and with high specificity. In this way, clinicians may be provided with significant and timely guidance through the detection signal to implement individualized patient therapy. our research group will conduct further research.
